Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15ā000 women in 23 randomised trials.
Quick Take: Ovarian ablation or suppression significantly reduces breast cancer recurrence and improves survival, particularly in premenopausal women with hormone-sensitive disease.
š” Clinical Impact
- Mechanistic: Ovarian ablation/suppression directly lowers circulating estrogen levels, a critical driver for the growth of ER-positive breast cancers.
- Clinical/Systemic: This intervention offers a robust, non-chemotherapy-based option for recurrence risk reduction, especially relevant for younger patients where fertility preservation is a concern.
š Evidence Breakdown Evidence Grade: š¢ 9/10 (Meta-analysis of Randomized Controlled Trials)
Analysis: This patient-level meta-analysis aggregates high-quality data from 23 randomized trials, representing a gold standard for evidence synthesis. The sheer sample size (15,000 women) provides substantial statistical power. While the meta-analysis likely accounts for some heterogeneity, variations in the specific methods of ablation/suppression (surgical vs. pharmacological, duration) and patient populations (age, menopausal status, prior treatments) could introduce residual variability.
Note: The long-term durability of benefit and potential late toxicities beyond the reported follow-up periods warrant ongoing consideration.
š©ŗ Practice Recommendation [Standard of Care]: Integrate judicious ovarian ablation/suppression into adjuvant treatment algorithms for eligible premenopausal women with hormone-sensitive breast cancer, particularly those with higher-risk disease.
- Discuss Ovarian Function Suppression (OFS): For premenopausal women with ER-positive breast cancer, discuss OFS (medical or surgical) as part of adjuvant therapy discussions, especially in conjunction with endocrine therapy.
- Referral: Ensure timely referral to endocrinology or gynecologic oncology for management of OFS where appropriate.